News
Two UBS Advisors in Boston, MA, Named to the Forbes/SHOOK Top 250 Wealth Advisors List
UBS Wealth Management USA announced today that two Financial Advisors in Boston, MA, Max Pecker and Sean Dillon, have been named to the Forbes/SHOOK Research Top 250 Wealth Advisors list for 2021.
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005635/en/
Vifor Pharma and Cara Therapeutics (Nasdaq:CARA)
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1
Regulatory News:
Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient
Vifor Pharma erzielt im 1. Halbjahr 2021 starkes Wachstum und bestätigt Jahresprognose1
Regulatory News:
Die Vifor Pharma Gruppe erzielte im 1. Halbjahr 2021 ein profitables Umsatzwachstum dank einer starken Erholung von Ferinject®/Injectafer® mit einem Umsatzplus von 22.8% zu kWk
ABB to Divest Mechanical Power Transmission Division (Dodge) to RBC Bearings for $2.9 Billion
ABB today announced it has signed a definitive agreement to divest its Mechanical Power Transmission division (Dodge) to RBC Bearings Incorporated (Nasdaq: ROLL), for $2.9 billion in cash. The
ABB: Q2 2021 Results
ABB (SWX:ABBN):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721006023/en/
Ad hoc Announcement pursuant to Art. 53 Listing Rules
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain
Abbas Hussain zum neuen Chief Executive Officer von Vifor Pharma ernannt
Regulatory News:
Abbas Hussain (56, britischer Staatsbürger) verfügt über eine mehr als 30-jährige erfolgreiche und internationale Karriere als Führungskraft im Gesundheitssektor. Von 2008 bis
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
Regulatory News:
Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in
RecovR Lot Management and Theft Recovery Solution Rolls Out Nationwide
RecovR, a two-in-one lot management and theft recovery solution by Kudelski IoT – a unit of the Kudelski Group (SIX:KUD), a leading global technology and security provider – announced today that it
93rd Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19
93. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 93. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt. Angesichts der anhaltenden
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21)
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high
ABB: Q1 2021 Results
ABB (ABBN: SIX Swiss Ex):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005972/en/
KEY FIGURES
ABB Issues Trading Update Following Better-Than-Anticipated Performance in Q1
ABB is publishing preliminary information on its first-quarter 2021 results, which according to the information available to the company, is better than the latest company guidance and current
ABB Launches New Share Buyback Program
ABB will launch on April 9, 2021 its previously announced follow-up share buyback program of up to $4.3 billion. Based on the current share price this represents a maximum of approximately 137
Five UBS Advisors in Greater New England Named to Forbes/SHOOK Top Women Wealth Advisors List
UBS Wealth Management USA announced today that five Financial Advisors in the firm’s Greater New England Market have been named to the Forbes/SHOOK Research Top Women Wealth Advisors list for 2021
Kudelski IoT keySTREAM™ Delivers the Most Advanced End-to-End IoT Security & Device Management Solution for Developers
Kudelski IoT, a division of the Kudelski Group (SIX: KUD.S), the world leader in digital security and IoT solutions, today announced the availability of the Kudelski IoT keySTREAM Development Kit
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
Regulatory News:
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a
ABB Plans to Launch New Share Buyback Following Completion of Initial Program
ABB has completed its initial share buyback program that was launched in July 2020 as part of the company’s commitment to return to shareholders cash proceeds from the Power Grids divestment of
ABB shareholders approve all proposals at 2021 Annual General Meeting
The shareholders of ABB have approved all the proposals by the company’s Board of Directors at its 2021 Annual General Meeting. Due to the extraordinary circumstances and in line with applicable
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq